Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · GENNEX LABORATORIES LTD. · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
GENNEX LABORATORIES LTD.
BSE: 531739
BSE: 531739
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
GENNEX LABORATORIES LTD.
StateQ4 FY26 filed
Last close · 8 Oct 2026₹9.79
Market cap₹0.2k cr
TTM P/E · P/B · EV/EBITDA12.1 · 1.02 · 9.1
GENNEX LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 61 | 66 | 87 | 138 | 173 |
| EBITDA (ex other income) | 5 | 5 | 17 | 17 | 22 |
| margin % | 8.8 | 7.2 | 19.6 | 12.0 | 12.6 |
| Owners' profit | 4 | 5 | 13 | 18 | 19 |
| EPS, as reported (₹) | 0.33 | 0.35 | 0.67 | 0.79 | 0.76 |
| ROE % · ROCE % | 9.0 · 13.6 | 5.7 · 7.5 | 7.5 · 10.3 | 9.3 · 11.8 | 9.0 · 9.9 |
| Debt / equity (x) | 0.23 | 0.01 | 0.03 | 0.05 | 0.15 |
| Cash from operations | 7 | 24 | (47) | (11) | (64) |
| Capex | (0) | (40) | 0 | (9) | (12) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GENNEX LABORATORIES LTD. · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 28 | 32 | 38 | 40 | 34 | 37 | 40 | 61 |
| Profit before tax | 6 | 6 | 6 | 4 | 6 | 6 | 7 | 5 |
| Net profit | 5 | 5 | 5 | 3 | 5 | 6 | 6 | 4 |
| EPS (₹) | 0.20 | 0.21 | 0.22 | 0.13 | 0.22 | 0.21 | 0.22 | 0.16 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,22,229 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,48,067 | 84.9 | 14.80 | 64.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,270 | 73.8 | 8.89 | 38.8 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,10,978 | 24.8 | 3.75 | 14.4 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,07,937 | 98.6 | 19.87 | 60.1 | 16.4 | 17.2 | 7.2 | 32.0 |
| CIPLA LTD | 1,05,570 | 31.3 | 3.06 | 16.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| DR. REDDY S LABORATORIES | 98,530 | 30.5 | 2.58 | 13.2 | 10.9 | 13.0 | 12.1 | 15.0 |
| MANKIND PHARMA LIMITED | 98,294 | 48.1 | 5.94 | 27.1 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.1 | 31.2 | 26 of 158 | 84% |
| P/B | 1.0 | 3.1 | 22 of 163 | 87% |
| ROCE | 8.4 | 10.8 | 110 of 183 | 40% |
| ROE | 9.0 | 9.8 | 92 of 166 | 45% |
| Debt / Equity | 0.1 | 0.2 | 83 of 166 | 50% |
| EBITDA margin | 11.3 | 17.5 | 113 of 165 | 32% |
| Revenue growth | 51.2 | 16.3 | 21 of 161 | 88% |
| Profit growth | 45.2 | 30.9 | 68 of 158 | 57% |
| Market cap | 238 | 857 | 109 of 181 | 40% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GENNEX LABORATORIES LTD. · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Oct 2026 · Gennex Laboratories 41st AGM: All 4 resolutions passed with over 99.8% majority | board shareholder meetings | medium | — | — |
| 30 Sept 2026 · Gennex Labs appoints Dipankar Dasgupta as Independent Director | management changes | medium | — | — |
| 30 Sept 2026 · Gennex Labs 41st AGM held on Sep 30, 2026; four resolutions transacted | board shareholder meetings | low | — | — |
| 22 Sept 2026 · Trading Window Closure Ahead of Q2 FY26-27 Results | compliance | minimal | — | — |
| 9 Sept 2026 · Gennex Laboratories files 41st AGM newspaper notice | compliance | minimal | — | — |
| 8 Sept 2026 · Subsidiary Deccan Remedies gets drug licence for 6 new products | business updates | medium | — | — |
| 8 Sept 2026 · Gennex Labs files 41st Annual Report and AGM notice; profit up | board shareholder meetings | medium | — | — |
| 4 Sept 2026 · Book closure for 41st AGM from Sept 23 to Sept 30, 2026 | corporate actions | low | — | — |
| 4 Sept 2026 · Board approves FY26 report, fixes 41st AGM on Sept 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 27 Aug 2026 · Board Meeting on Sept 4 to consider 41st AGM matters | board shareholder meetings | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in